Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Fernando Ferro

Internal Medicine Baltimore, MD Medical Doctor

NPI 1245297258 CMS profile 55919

7602 Belair Rd, Baltimore, MD 21236

Open in the dashboard

General payments

$1,863

83 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Fernando Ferro of Baltimore, MD is reported in the CMS Open Payments database as having received $1,863 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $16 1
2023 General $46 2
2022 General $19 1
2021 General $134 2
2020 General $215 13
2019 General $1,433 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fernando Ferro
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Fernando Ferro were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Fernando Ferro Internal Medicine median Middle half National median
2019 $1,433 $159 $48–$570 $163
2020 $215 $119 $33–$402 $114
2021 $134 $135 $37–$521 $132
2022 $19 $141 $42–$496 $149
2023 $46 $149 $45–$519 $160
2024 $16 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AstraZeneca Pharmaceuticals LP $448 22 payments
  2. Lilly USA, LLC $336 20 payments
  3. GlaxoSmithKline, LLC. $137 3 payments
  4. Amgen Inc. $123 5 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $119 1 payment
  6. Astellas Pharma US Inc $99 1 payment
  7. Valeritas, Inc. $94 1 payment
  8. AbbVie, Inc. $77 4 payments
  9. Allergan Inc. $76 4 payments
  10. Genentech USA, Inc. $71 3 payments
  11. Other $283 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,756 81 payments
  2. Education $107 2 payments
Products named General payments · program years 2019–2024
  1. FARXIGA $448 22 payments
  2. TRULICITY $193 16 payments
  3. BASAGLAR $180 15 payments
  4. SYMBICORT $163 1 payment
  5. PULMICORT RESPULES $163 1 payment
  6. JARDIANCE $154 13 payments
  7. TRELEGY ELLIPTA $122 1 payment
  8. Kerendia $119 1 payment
  9. Repatha $101 4 payments
  10. V-GO $94 1 payment
  11. Other $895 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 152 drugs

Part D claims

12,595

Median for Internal Medicine: 777

Drug cost

$988,065

Median for Internal Medicine: $73,373

Branded share of claims

17%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 245 $236,679
Trulicity Dulaglutide Brand 48 $101,529
Ozempic Semaglutide Brand 32 $80,246
Mounjaro Tirzepatide Brand 52 $73,735
Jardiance Empagliflozin Brand 38 $58,562
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 33 $40,687
Januvia Sitagliptin Phosphate Brand 24 $33,195
Myrbetriq Mirabegron Brand 34 $29,142
Creon Lipase/Protease/Amylase Brand 12 $23,873
Breo Ellipta Fluticasone/Vilanterol Brand 29 $21,910

The 10 drugs with the highest cost, of 152 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$224,213

Of which drugs: $29,906

Medicare patients

806

Average age 75

Services billed

5,284

442 women, 364 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 35%
Diabetes 26%
Ischemic heart disease 23%
Chronic kidney disease 20%
Depression 17%
Osteoporosis 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 208 209 $17,100
Pcv20 vaccine im 90677 Office 37 37 $10,715
Influenza vaccine, trivalent derived from cell cultures 90661 Office 13 13 $469
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 32 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record